NeoGenomics, Inc. (NEO)
NASDAQ: NEO · Real-Time Price · USD
9.99
-0.10 (-0.99%)
Apr 25, 2025, 11:43 AM EDT - Market open
NeoGenomics Revenue
In the year 2024, NeoGenomics had annual revenue of $660.57M with 11.65% growth. NeoGenomics had revenue of $172.00M in the quarter ending December 31, 2024, with 10.57% growth.
Revenue (ttm)
$660.57M
Revenue Growth
+11.65%
P/S Ratio
1.93
Revenue / Employee
$300,257
Employees
2,200
Market Cap
1.29B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 660.57M | 68.92M | 11.65% |
Dec 31, 2023 | 591.64M | 81.92M | 16.07% |
Dec 31, 2022 | 509.73M | 25.40M | 5.24% |
Dec 31, 2021 | 484.33M | 39.88M | 8.97% |
Dec 31, 2020 | 444.45M | 35.62M | 8.71% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.90B |
NEO News
- 3 days ago - NeoGenomics to Showcase PanTracer LBx Validation Study at AACR Annual Meeting - Business Wire
- 17 days ago - NeoGenomics to Report First Quarter 2025 Financial Results on April 29, 2025 - Business Wire
- 18 days ago - NeoGenomics Completes Acquisition of Pathline - Business Wire
- 24 days ago - Tony Zook Assumes Role as Chief Executive Officer of NeoGenomics - Business Wire
- 6 weeks ago - NeoGenomics Expands Oncology Testing Reach in the Northeast with Acquisition of Pathline - Business Wire
- 2 months ago - NeoGenomics: Decent Fundamentals, But Still Overvalued - Seeking Alpha
- 2 months ago - NeoGenomics to Participate in Upcoming Investor Conferences - Business Wire
- 2 months ago - NeoGenomics, Inc (NEO) Q4 2024 Earnings Call Transcript - Seeking Alpha